The economics of biosimilars

American Health and Drug Benefits

Volumn 6, Issue 8, 2013, Pages 469-477

  Blackstone, Erwin A ^a   Fuhr Jr , Joseph P ^b  

^a TEMPLE UNIVERSITY   (United States)

^b WIDENER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BIOLOGICAL PRODUCT; BIOSIMILAR AGENT; ERYTHROPOIETIN; ETANERCEPT; GENERIC DRUG; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; INFLIXIMAB; INSULIN LISPRO; LONG ACTING DRUG; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OBINUTUZUMAB; PALIVIZUMAB; PERTUZUMAB; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; SHORT ACTING DRUG; TRASTUZUMAB; TRASTUZUMAB EMTANSINE;

DRUG COST; DRUG INDUSTRY; DRUG INFORMATION; DRUG MANUFACTURE; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; ECONOMIC ASPECT; EUROPEAN UNION; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; PHYSICIAN ATTITUDE; REVIEW; TREND STUDY; UNITED STATES;

EID: 84886697585     PISSN: 19422962     EISSN: 19422970     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Emerton DA. Profitability in the biosimilars market: can you translate scientifc excellence into a healthy commercial return? BioProcess Int. 2013;11(6 suppl):6-14,23.
2. Blackstone EA, Fuhr JP. The future of competition in the biologics market. Temple J Sci Technol Environ Law. 2012;31:1-30.
3. Heled Y. Why primary patents covering biologics should be unforceable against generic applicants under the Biologics Price Competition and Innovation Act. Ann Health Law. 2012;21(spec ed):211-221.
4. Silver S. Industry surveys: biotechnology. Standard & Poor's. February 2013.
5. Palmer E. Conquering the complexities of biologics to get to biosimilars. Fierce PharmaManufacturing. March 26, 2013. www.fercepharmamanufacturing.com/special-report/conquering-complexities-biologics-get-biosimilars. Accessed September 19, 2013.
6. Van Arnum P. Biosimilars: market weaknesses and strengths: biosimilars represent an emerging niche in the biopharmaceutical market, but how strong is their true potential? PharmaTech.com. July 11, 2012. www.pharmtech.com/pharmtech/Most?Market-Weaknesses-and-Strengths/ArticleStandard/Article/detail/780563. Accessed September 20, 2013.
7. European Commission. What you need to know about biosimilar medicinal products. Consensus information paper. 2013. http://ec.europa.eu/enterprise/sectors/healthcare/fles/docs/biosimilars_report_en.pdf. Accessed September 20, 2013.
8. IMS Health. Shaping the biosimilars opportunity: a global perspective on the evolving biosimilars landscape. December 2011. www.imshealth.com/ims/Global/Content/Home%20Page%20Content/IMS%20News/Biosimilars_Whitepaper.pdf. Accessed September 20, 2013.
9. Kitamura M, Kang S. First copy of J&J's $6 billion Remicade wins EMA backing. Bloomberg. July 1, 2013. www.bloomberg.com/news/2013-06-28/frst-copy-of-j-j-s-6-billion-remicade-wins-ema-backing.html. Accessed September 20, 2013.
10. Tapella M. Biosimilars have arrived. ScientiaAdvisors Blog. January 6, 2012. www.scientiaadv.com/blog/2012/01/06/biosimilars-have-arrived/. Accessed March 28, 2013.
11. Declerck PJ, Simoens S. A European perspective on the market accessibility of biosimilars. Biosimilars. 2012;2:33-40.
12. ViewPoints: has Sandoz got the biosimilars race all tied up? FirstWord Pharma. June 26, 2013. www.frstwordpharma.com/node/1112747#axzz2fRXgaw4B. Accessed September 20, 2013.
13. Eun-kyung S, So-eui R. Samsung to invest $389 million in biosimilars: report. Reuters. July 15, 2009. www.reuters.com/article/2009/07/15/us-samsung-bio-idUSTRE56E0ZP20090715. Accessed September 20, 2013.
14. Lovenworth SJ. The new biosimilar era: the basics, the landscape, and the future. Bloomberg Law. 2012. http://about.bloomberglaw.com/practitioner-contributions/the-new-biosimilar-era-the-basics-the-landscape-and-the-future/. Accessed September 20, 2013.
15. Brennan Z. Biosimilars: is the market getting too much attention? BioPharma-Reporter.com. March 6, www.biopharma-reporter.com/Markets-Regulations/Biosimilars-Is-the-Market-Getting-Too-Much-Attention. Accessed September 20, 2013.
16. Weaver C, Whalen J, Rockoff JD. Biotech drugs still won't copy. Wall Street Journal. February 26, 2013. http://online.wsj.com/article/SB10001424127887323864304578318111144984632.html. Accessed September 20, 2013.
17. IMS Institute for Healthcare Informatics. Declining medicine use and costs: for better or worse? A review of the use of medicines in the United States in 2012. May 2013. www.imshealth.com/deployedfles/ims/Global/Content/Insights/IMS%20Institute%20for%20Healthcare%20Informatics/2012%20U.S.%20Medicines%20Report/2012_U.S.Medicines_Report.pdf. Accessed September 30, 2013.
18. Copley C. Analysis: Roche stays a step ahead of copycat drugmakers. Reuters. March 25, 2013. www.reuters.com/article/2013/03/25/us-roche-biosimilars-idUSBRE92O0EH20130325. Accessed September 20, 2013.
19. Aris R. Biosimilars 2012-what does the current landscape look like? pharmapho-rum. March 8, 2012. www.pharmaphorum.com/articles/biosimilars-2012---what-does-the-current-landscape-look-like. Accessed September 20, 2013.
20. PR Newswire. The road ahead for biosimilars in Europe, says Frost & Sullivan: huge market opportunity from impending patent expiry of blockbuster biologics. Press release. March 21, 2012. www.prnewswire.co.uk/news-releases/the-road-ahead-for-biosimilars-in-europe-says-frost-sullivan-144597775.html. Accessed September 20, 2013.
21. Grant Thornton India. Bio-dynamism: insights into the biosimilars market: an overall perspective. 2013. www.grantthornton.in/assets/BioAsia_2013.pdf. Accessed September 20, 2013.
22. Hernandez R. Implications of biosimilar use: a market perspective. Spec Pharm Times. Epub 2013 March 13.
23. Leaf C. Do clinical trials work? New York Times Sunday Review. July 13, 2003. www.nytimes.com/2013/07/14/opinion/sunday/do-clinical-trials-work.html?pagewanted=all&_r=0. Accessed September 20, 2013.
24. Biosimilar trastuzumab made in tobacco plants. GaBi Online. January 18, 2013. http://gabionline.net/Biosimilars/News/Biosimilar-trastuzumab-made-in-tobacco-plants. Accessed September 20, 2013.
25. Rituximab biosimilar successfully produced in plants. GaBi Online. October 10, 2011. www.gabionline.net/Biosimilars/News/Rituximab-biosimilar-successfully-produced-in-plants. Accessed September 20, 2013.
26. Wallack T. FDA rejects Genzyme request for Myozyme. April 22, 2008. The Boston Globe. www.boston.com/business/healthcare/articles/2008/04/22/fda_rejects_genzyme_request_for_myozyme/. Accessed September 20, 2013.
27. Genzyme receives FDA approval for Lumizyme for Pompe disease. Business Wire. May 25, 2010. www.businesswire.com/news/home/20100525006514/en/Genzyme-Receives-FDA-Approval-Lumizyme-Pompe-Disease. Accessed September 20, 2013.
28. Gaffney A. New EMA guideline establishes framework for biosimilars, use of international comparator studies. Regulatory Focus. May 2, 2013. www.raps.org/focus-online/news/news-article-view/article/3354.aspx. Accessed September 20, 2013.
29. Graeser D. Industry voices: biosimilars and trade secrets. FierceBiotech. October 24, 2012. www.fercebiotech.com/story/industry-voices-biosimilars-and-trade-secrets/2012-10-24. Accessed September 20, 2013.
30. Zuhn D. WLF submits comments on Abbott's citizen petition on biosimilars. Patent Docs. March 6, 2013. www.patentdocs.org/2013/03/wlf-submits-comments-on-abbotts-citizen-petition-on-biosimilars.html. Accessed September 20, 2013.
31. Gaffney A. Data submitted before 2010 shouldn't be used to approve biosimilars, group says. Regulatory Focus. April 19, 2013. www.raps.org/focus-online/news/news-article-view/article/3234. Accessed September 20, 2013.
32. Pharma companies sue EMA to block release of data. GaBi Online. March 15, 2013. www.gabionline.net/Biosimilars/General/Pharma-companies-sue-EMA-to-block-release-of-data. Accessed September 20, 2013.
33. Gaffney A. In major reversal, EMA ordered by EU court to halt clinical trials transparency initiative. Regulatory Focus. April 30, 2013. www.raps.org/focus-online/news/news-article-view/article/3309. Accessed September 20, 2013.
34. Carroll J. Roche's next-gen Rituxan candidate impresses in first look at PhIII data. FierceBiotech. May 16, 2013. www.fercebiotech.com/story/roches-next-gen-rituxan-candidate-impresses-frst-look-phiii-data/2013-05-16. Accessed September 20, 2013.
35. Gryta T; for Dow Jones Newswires. Hospira learning valuable lessons in European biosimilar market. Press release. October 1, 2009. http://english.capital.gr/news.asp?id=824518. Accessed September 20, 2013.
36. Dinwoodie N. Biobetters and the future biologics market BioPharm. November 1, 2011. www.biopharminternational.com/biopharm/Upstream???????and-the-Future-Biologics-Market/ArticleStandard/Article/detail/746281. Accessed September 20, 2013.
37. Copley C. Lonza CEO says reviewing biosimilar venture with Teva. Reuters. March 30, 2013. www.reuters.com/article/2013/03/30/us-lonza-teva-biosimilars-idUSBRE92T02L20130330. Accessed September 20, 2013.
38. Carroll J. Biosimilars face big delays as blockbuster knockoffs hit a roadblock. FierceBiotech. February 27, 2013. www.fercebiotech.com/story/biosimilars-face-big-delays-blockbuster-knockoffs-hit-roadblock/2013-02-27. Accessed September 20, 2013.
39. Barnes K, Kim K, Park SY. Celltrion slides to third in race for Roche rituximab biosimilar with planned 2H13 phase III trial start. Financial Times. April 19, 2013. www.ft.com/cms/s/2/dcad130c-a8fb-11e2-a096-00144feabdc0.html#axzz2fSCIazDQ. Accessed September 20, 2013.
40. McBride R. Report: don't count Celltrion out of Rituxan biosim race. FierceBio-tech. April 19, 2013. www.fercebiotech.com/story/report-dont-count-celltrion-out-rituxan-biosim-race/2013-04-19. Accessed September 20, 2013.
41. Amgen's biosimilar plans. GaBi Online. April 5, 2013. www.gabionline.net/Biosimilars/News/Amgen-s-biosimilar-plans. Accessed September 20, 2013.
42. Kitamura M, Wainer D. Biosimilars lure major drugmakers into the generics biz. BloombergBusinessweek. March 21, 2013. www.businessweek.com/articles/2013-03-21/biosimilars-lure-major-drugmakers-into-the-generics-biz. Accessed September 20, 2013.
43. Questions over US biosimilars pathway in light of Teva's BLA. GaBi Online. May 20, 2011. www.gabionline.net/Biosimilars/General/Questions-over-US-biosimilars-pathway-in-light-of-Teva-s-BLA. Accessed September 20, 2013.